



Stopping Seizures With Carbon Dioxide

Five Percent CO₂ Is a Potent, Fast-Acting Inhalation Anticonvulsant.

Tolner EA, Hochman DW, Hassinen P, Otáhal J, Gaily E, Haglund MM, Kubová H, Schuchmann S, Vanhatalo S, Kaila K. *Epilepsia* 2011;52(1):104–114.

PURPOSE: CO₂ has been long recognized for its anticonvulsant properties. We aimed to determine whether inhaling 5% CO₂ can be used to suppress seizures in epilepsy patients. The effect of CO₂ on cortical epileptic activity accompanying behavioral seizures was studied in rats and nonhuman primates, and based on these data, preliminary tests were carried out in humans. **METHODS:** In freely moving rats, cortical afterdischarges paralleled by myoclonic convulsions were evoked by sensorimotor cortex stimulation. Five percent CO₂ was applied for 5 min, 3 min before stimulation. In macaque monkeys, hypercarbia was induced by hypoventilation while seizure activity was electrically or chemically evoked in the sensorimotor cortex. Seven patients with drug resistant partial epilepsy were examined with video-EEG (electroencephalography) and received 5% CO₂ in medical carbogen shortly after electrographic seizure onset. **RESULTS:** In rats, 5% CO₂ strongly suppressed cortical afterdischarges, by approximately 75%, whereas responses to single-pulse stimulation were reduced by about 15% only. In macaques, increasing pCO₂ from 37 to 44–45 mm Hg (corresponding to inhalation of 5% CO₂ or less) suppressed stimulation-induced cortical afterdischarges by about 70% and single, bicuculline-induced epileptiform spikes by approximately 25%. In a pilot trial carried out in seven patients, a rapid termination of electrographic seizures was seen despite the fact that the application of 5% CO₂ was started after seizure generalization. **CONCLUSIONS:** Five percent CO₂ has a fast and potent anticonvulsant action. The present data suggest that medical carbogen with 5% CO₂ can be used for acute treatment to suppress seizures in epilepsy patients.

Commentary

Although it has been known for more than 80 years that inhalation of an increased concentration of CO₂ may suppress seizures (1, 2), this phenomenon has not been exploited as a clinical treatment. Nonetheless, there is extensive experimental and clinical literature documenting that CO₂ concentrations of 10% and above can block or terminate a variety of seizures in animals and humans (3, 4), including electroshock seizures in psychiatric patients (5). The purpose of the current study by Tolner and colleagues is not only to revive attention for this neglected area of investigation but also to demonstrate the efficacy of 5% CO₂, a clinically appropriate concentration, and to carry out a preliminary study of this intervention to treat acute seizures in the epilepsy monitoring unit.

For the experimental animals in this study, hypercapnia was induced by pumping 5% CO₂ in air into a chamber holding the rats, or, in the macaques, by hypoventilation with artificial ventilation to adjust the pCO₂ to the level that would be expected from breathing 5% CO₂. Spontaneous seizures were not studied in animals. Rather, these interventions were shown to shorten afterdischarges induced by electrical cortical stimulation in both the rats and monkeys and reduce the

amplitude and frequency of spikes induced by application of bicuculline to motor cortex. Acetazolamide produced a similar, but smaller, shortening of afterdischarges in the rats.

The human trial was done in patients with medically intractable localization-related epilepsy. Four patients were monitored with scalp electrodes, and three with subdural electrode arrays. As soon as possible after the electrographic seizure discharge spread bilaterally, a mixture of 5% CO₂ and 95% O₂ was applied by mask and then stopped when the seizure terminated. While 13 seizures were treated, 7 seizures from 5 of these patients were chosen as control events because they had semiology similar to the treated seizures. Application of the gas occurred at a mean of 40 seconds after the beginning of the electrographic seizures, and seizure duration was reduced by an average of 30% compared with the seven selected untreated seizures. No monitoring of pCO₂ or pO₂ is described.

It appears that hypercapnia suppresses and terminates seizures by altering pH, rather than by affecting cerebral blood flow. The antiepileptic effects of acetazolamide may also be due to lowering of brain pH (6). Moreover, respiratory alkalosis may be responsible for the activating effects of hyperventilation on epileptiform activity, and for fever-induced seizures (7). These facts indicate the need for clinicians to avoid respiratory alkalosis when ventilating patients with status epilepticus and other acute severe seizures.

In vivo studies demonstrate strong inhibition of neuronal activity with acidosis (8). This may be mediated by direct ac-




tions on voltage and ligand-gated ion channels (9). There is an acid-sensing ion channel (ASIC1a) which regulates neuronal excitability with exquisite sensitivity to extracellular pH. There is evidence that acidosis activates inhibitory interneurons through ASIC1a (9). In addition, there is evidence that lowering of intracellular pH leads to increased extracellular adenosine, activation of adenosine A1 receptors and a decrease in excitatory synaptic transmission (10). This leads to decreased burst firing in a hippocampal slice seizure model. All of these mechanisms play a part in the self-termination of experimental seizures; it is logical that they would be activated more strongly with lowering of cerebral pH from respiratory acidosis.

The antiepileptic properties of hypercapnia are convincingly demonstrated by the published experimental and clinical studies, and the present study demonstrates its feasibility as a clinical treatment. Its introduction into everyday practice would first require a randomized controlled trial to demonstrate efficacy and safety. Patients could be randomized between 100% O₂ and the mixture of 5% CO₂ and 95% O₂ in a blinded fashion, with an adequate number of events treated to address the typical wide variability of spontaneous seizure duration and evolution. Safety monitoring should include measurement of pCO₂, to ensure that unsafe exacerbation of hypercapnia and systemic acidosis does not occur with any prolonged convulsive seizures that are refractory to the treatment. Such a clinical trial is realistic and worthwhile. Carbon dioxide inhalation could prove to be an easy and inexpensive intervention for acute seizures in the hospital, and possibly in the home as well.

by John W. Miller, MD, PhD

References

1. Lennox WG. The effect on epileptic seizures of varying the composition of the respired air. *J Clin Invest* 1928;6:23–24.
2. Lennox WG, Gibbs FA, Gibbs EL. Effect on the electroencephalogram of drugs and conditions which influence seizures. *Arch Neurol Psychiatry* 1936;36:1236–1245.
3. Woodbury DM, Rollins LT, Henrie JR, Jones JC, Sato T. Effects of carbon dioxide and oxygen on properties of experimental seizures in mice. *Am J Physiol* 1955;184:202–208.
4. Caspers H, Speckmann EJ. Cerebral pO₂, pCO₂ and pH: Changes during convulsive activity and their significance for spontaneous arrest of seizures. *Epilepsia* 1972;13:699–725.
5. Gyarfás K, Pollock GH, Stein SN. Central inhibitory effects of carbon dioxide; convulsive phenomena. *Proc Soc Exp Biol Med* 1949;70:292.
6. Rollins DE, Withrow CD, Woodbury DM. Tissue acid-base balance in acetazolamide-treated rats. *J Pharmacol Exp Ther* 1970;173:535–540.
7. Schuchmann S, Schmitz D, Rivera C, Vanhatalo S, Salmen B, Mackie K, Sipilä ST, Voipio J, Kaila K. Experimental febrile seizures are precipitated by a hyperthermia-induced respiratory alkalosis. *Nat Med* 2006;12:817–823.
8. Kaila K, Ransom B. *pH and Brain Function*. New York: Wiley-Liss, 1998.
9. Ziemann AE, Schnitzler MK, Albert GW, Severson MA, Howard MD, Welsh MJ, Wemmie JA. Seizure termination by acidosis depends on ASIC1a. *Nat Neurosci* 2008;11:816–822.
10. Dulla CG, Frenguelli BG, Staley KJ, Masino SA. Intracellular acidification causes adenosine release during states of hyperexcitability in the hippocampus. *J Neurophysiol* 2009;102:1984–1993.



American Epilepsy Society

Epilepsy Currents Journal

Disclosure of Potential Conflicts of Interest

Section #1 Identifying Information

1. Today's Date: ____April 3,2011_____
2. First Name ____John_____ Last Name ____Miller_____ Degree __M.D., Ph.D.____
3. Are you the Main Assigned Author? Yes No
If no, enter your name as co-author _____
4. Manuscript/Article Title:____Stopping seizures with carbon dioxide _____
5. Journal Issue you are submitting for: _____11.4r_____

Section #2 The Work Under Consideration for Publication

Did you or your institution at any time receive payment or services from a third party for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Complete each row by checking "No" or providing the requested information. If you have more than one relationship just add rows to this table.

Type	No	Money Paid to You	Money to Your Institution*	Name of Entity	Comments**
1. Grant	x				
2. Consulting fee or honorarium	x				
3. Support for travel to meetings for the study or other purposes	x				
4. Fees for participating in review activities such as data monitoring boards, statistical analysis, end point committees, and the like	x				
5. Payment for writing or reviewing the manuscript	x				
6. Provision of writing assistance, medicines, equipment, or administrative support.	x				
7. Other	x				

* This means money that your institution received for your efforts on this study.

** Use this section to provide any needed explanation.

Section #3 Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the “Add” box. You should report relationships that were present during the 36 months prior to submission.

Complete each row by checking “No” or providing the requested information. If you have more than one relationship just add rows to this table.

Type of relationship (in alphabetical order)	No	Money Paid to You	Money to Your Institution*	Name of Entity	Comments**
1. Board membership	x				
2. Consultancy	x				
3. Employment	x				
4. Expert testimony	x				
5. Grants/grants pending			x	NIH	Various, including clinical trials and animal research relevant to medical and surgical treatment of epilepsy
			x	King Pharmaceuticals; UCB Pharma	Various industry sponsored drug studies
6. Payment for lectures including service on speakers bureaus	x				
7. Payment for manuscript preparation.	x				
8. Patents (planned, pending or issued)			x		Device to treat intractable epilepsy; seizure detection programs
9. Royalties	x				
10. Payment for development of educational presentations	x				
11. Stock/stock options	x				
12. Travel/accommodations/meeting expenses unrelated to activities listed.**	x				
13. Other (err on the side of full disclosure)	x				

* This means money that your institution received for your efforts.

** For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.

Section #4 Other relationships

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No other relationships/conditions/circumstances that present a potential conflict of interest.

Yes, the following relationships/conditions/circumstances are present:

Thank you for your assistance.
Epilepsy Currents Editorial Board